Omnicell (NASDAQ:OMCL) Sets New 12-Month Low at $25.45

Omnicell, Inc. (NASDAQ:OMCL)’s share price reached a new 52-week low on Thursday . The stock traded as low as $25.45 and last traded at $25.73, with a volume of 13511 shares traded. The stock had previously closed at $26.22.

Wall Street Analysts Forecast Growth

Separately, Benchmark reissued a “buy” rating and issued a $38.00 target price on shares of Omnicell in a research note on Tuesday, April 30th. One analyst has rated the stock with a sell rating, three have given a hold rating and three have given a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $42.20.

Omnicell Trading Down 1.8 %

The company has a debt-to-equity ratio of 0.48, a current ratio of 2.38 and a quick ratio of 2.13. The stock has a 50 day moving average of $29.48 and a 200 day moving average of $30.67.

Omnicell (NASDAQ:OMCL) last released its earnings results on Thursday, May 2nd. The company reported ($0.14) EPS for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.17. Omnicell had a positive return on equity of 2.41% and a negative net margin of 1.91%. The business had revenue of $246.15 million for the quarter, compared to analysts’ expectations of $235.70 million. As a group, sell-side analysts anticipate that Omnicell, Inc. will post 0.2 earnings per share for the current fiscal year.

Institutional Trading of Omnicell

Institutional investors have recently added to or reduced their stakes in the business. Panagora Asset Management Inc. purchased a new stake in Omnicell during the fourth quarter valued at about $1,319,000. Vanguard Group Inc. boosted its position in Omnicell by 15.1% during the third quarter. Vanguard Group Inc. now owns 5,137,084 shares of the company’s stock valued at $231,374,000 after buying an additional 674,824 shares during the period. Pacer Advisors Inc. boosted its position in Omnicell by 321,488.8% during the fourth quarter. Pacer Advisors Inc. now owns 1,058,027 shares of the company’s stock valued at $39,814,000 after buying an additional 1,057,698 shares during the period. Cadian Capital Management LP purchased a new stake in Omnicell during the fourth quarter valued at about $2,446,000. Finally, Public Sector Pension Investment Board purchased a new stake in Omnicell during the third quarter valued at about $2,517,000. 97.70% of the stock is currently owned by hedge funds and other institutional investors.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.